Pulse Biosciences Inc. (NASDAQ:PLSE) shares soared in pre-market trading Friday after the company revealed positive results from a study of its treatment for skin lesions.
The stock jumped 14.7% to US$20.84 in pre-market trading.
The California-based company’s non-thermal Nano-Pulse Stimulation (NPS) technology held up well in a clinical trial for the treatment of seborrheic keratosis (SK), also known as senile warts. The results showed that 82% of treated lesions were rated as clear or mostly clear after 106 days.
"These impressive results demonstrate the reliable removal of SK lesions with a single treatment using NPS technology," said Thomas Rohrer, a dermatologic and Mohs skin cancer surgeon, in Boston.
“Pulse’s NPS technology has made a significant leap from very promising pre-clinical results to its first successful application in the removal of a common benign skin lesion with consistent results observed at each of the four top medical centers participating in the study,” added Rohrer who was a clinical investigator
The findings will be featured at the 2018